Amplia Therapeutics (Amplia Therapeutics) 5-Year EBITDA Growth Rate

: 27.00% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Amplia Therapeutics's EBITDA per Share for the six months ended in Sep. 2023 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 8.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 27.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amplia Therapeutics was 52.10% per year. The lowest was -25.70% per year. And the median was 17.70% per year.

Competitive Comparison

For the Biotechnology subindustry, Amplia Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics 5-Year EBITDA Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's 5-Year EBITDA Growth Rate falls into.

Amplia Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Amplia Therapeutics (OTCPK:INNMF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Amplia Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023